Real-world Reductions in Migraine and Headache Days for Patients With Migraine Initiating Fremanezumab in Germany

被引：0
|
作者：
Heinze, A. [1 ]
Totev, T. [2 ]
Krasenbaum, L. [3 ]
Terasawa, E. [4 ]
Akcicek, H. [5 ]
Hipp, J. [5 ]
Sun, R. [2 ]
Yim, E. [2 ]
Driessen, M. [5 ]
机构：
[1] Pain Clin Kiel, Migraine & Headache Ctr, Kiel, Germany
[2] Anal Grp Inc, Boston, MA USA
[3] Teva Branded Pharmaceut Prod R&D Inc, W Chester, PA USA
[4] Anal Grp Inc, New York, NY USA
[5] Teva Pharmaceut, Amsterdam, Netherlands
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2022年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO-075
引用
收藏
页码：419 / 419
页数：1
相关论文
共 50 条
  • [21] Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for chronic migraine in a US tertiary headache center
    Cohen, Fred
    Yuan, Hsiangkuo
    Dent, Kathryn
    Beucherie, Matthew
    Connolly, William
    Driessen, Maurice
    Krasenbaum, Lynda J.
    Carr, Karen
    Hopkins, Mary
    Marmura, Michael
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 127 - 128
  • [22] Real-world reductions in migraine-related healthcare resource utilization and medication use with fremanezumab treatment in US migraine patients using concomitant acute gepants
    Eugeni, P.
    Rooney, M. E.
    Saikali, N. P.
    Niu, Z.
    Driessen, M. T.
    Krasenbaum, L. J.
    Seminerio, M. J.
    McVige, J. W.
    HEADACHE, 2022, 62 : 158 - 158
  • [23] Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan
    Suzuki, Shiho
    Suzuki, Keisuke
    Shiina, Tomohiko
    Haruyama, Yasuo
    Hirata, Koichi
    FRONTIERS IN NEUROLOGY, 2023, 14
  • [24] Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study
    Ohtani, Seiya
    Watanabe, Narumi
    Ihara, Keiko
    Takahashi, Nobuyuki
    Miyazaki, Naoki
    Ishizuchi, Kei
    Takemura, Ryo
    Hori, Satoko
    Nakahara, Jin
    Takizawa, Tsubasa
    BMC NEUROLOGY, 2023, 23 (01)
  • [25] Effectiveness of fremanezumab treatment in patients with migraine headache
    Kikui, Shoji
    Daisuke, Danno
    Miyahara, Junichi
    Sugiyama, Hanako
    Ota, Kuniko
    Murakata, Kenji
    Kashiwaya, Yoshihiro
    Takeshima, Takao
    PAIN MEDICINE, 2024, 25 (11) : 664 - 670
  • [26] REAL-WORLD REDUCTIONS IN MIGRAINE-RELATED HEALTH CARE RESOURCE UTILIZATION AND COSTS FOR PATIENTS INITIATING FREMANEZUMAB: A 12-MONTH RETROSPECTIVE US CLAIMS ANALYSIS
    Driessen, M. T.
    Krasenbaum, L. J.
    Ramirez-Campos, V
    DiEgidio, R.
    Tian, M.
    Seminerio, M. J.
    VALUE IN HEALTH, 2022, 25 (07) : S346 - S346
  • [27] Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study
    Seiya Ohtani
    Narumi Watanabe
    Keiko Ihara
    Nobuyuki Takahashi
    Naoki Miyazaki
    Kei Ishizuchi
    Ryo Takemura
    Satoko Hori
    Jin Nakahara
    Tsubasa Takizawa
    BMC Neurology, 23
  • [28] Real-world evidence on fremanezumab for migraine treatment in Japan: a retrospective analysis
    Takizawa, T.
    Ohtani, S.
    Watanabe, N.
    Ihara, K.
    Takahashi, N.
    Miyazaki, N.
    Ishizuchi, K.
    Takemura, R.
    Hori, S.
    Nakahara, J.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [29] Real-world effectiveness of fremanezumab in patients with refractory migraine from a US tertiary headache center who switched from erenumab
    Yuan, H.
    Hopkins, M.
    Driessen, M. T.
    Krasenbaum, L. J.
    Seminerio, M. J.
    Marmura, M. J.
    HEADACHE, 2022, 62 : 156 - 157
  • [30] Real-World Experience of Erenumab in Patients with Migraine in Germany: The SPECTRE Study
    Gaul, Charly
    Gendolla, Astrid
    Holle, Dagny
    Goebel, Hartmut
    Koch, Mirja
    Baufeld, Caroline
    Weiss, Cordula
    PAIN AND THERAPY, 2024, 13 (06) : 1659 - 1678
12345